Login / Signup

[Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis].

M V ZhuravlevaM V DavydovskayaE V LuchininaT V ShelekhovaD O KurguzovaS Yu Serebrova
Published in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2020)
This review aims at describing clinical benefits and characteristics of the main highly effective disease modifying drugs (DMD) for multiple sclerosis (MS): alemtuzumab, cladribine tablets, ocrelizumab, natalizumab, fingolimod based on the efficacy and safety. The authors highlight that all MS DMDs have certain benefits and features that shall be considered in prescribing pharmacotherapy. Cladribine in tablets are comparable by the efficacy to other modern highly effective second-line drugs, have a high level of evidence and a favorable safety profile, as well as the most preferred benefit/risk ratio among other MS DMDs indicated for the treatment of highly active MS, which offers an advantage to the drug. The use of cladribine in tablets will contribute to further study of the efficacy and safety of this highly efficient drug for MS treatment.
Keyphrases
  • multiple sclerosis
  • highly efficient
  • white matter
  • mass spectrometry
  • primary care
  • emergency department
  • combination therapy
  • smoking cessation